Skip to main content
$131.88 -$1.66 (-1.2%)

04:00 PM EDT on 07/23/21

STAAR Surgical Company (NASDAQ:STAA)

CAPS Rating: 4 out of 5

The Company develops and manufactures minimally invasive visual implants and other ophthalmic products to improve or correct the vision of patients with cataracts and refractive conditions and distributes them worldwide.

Current Price $131.88 Mkt Cap $6.2B
Open $134.59 P/E Ratio 549.80
Prev. Close $131.88 Div. (Yield) $0.00 (0.0%)
Daily Range $127.33 - $134.59 Volume 234,914
52-Wk Range $45.47 - $161.71 Avg. Daily Vol. 406,830

Caps

How do you think NASDAQ:STAA will perform against the market?

Add Stock to CAPS Watchlist

All Players

195 Outperform
14 Underperform
 

All-Star Players

64 Outperform
5 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:STAA Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

RLScott (83.34)
Submitted July 01, 2020

Better alternative to Lasik SurgeryLimited CompetitionUpside potential

EclecticRecluse (< 20)
Submitted August 17, 2010

Increasingly Excessive P/E

Recent Community Commentary

Read the most recent pitches from players about STAA.

Recs

0
Member Avatar TMFjimhalley (35.27) Submitted: 6/12/2021 10:21:30 AM : Outperform Start Price: $145.09 NASDAQ:STAA Score: -12.76

The company's implantable collamer lenses to correct nearsightedness and other vision problems has the potential to be a disruptor in the industry. The company has improved revenue over the past 11 years and that doesn't seem to be slowing down.

Recs

0
Member Avatar Promoguy (56.84) Submitted: 6/9/2021 9:52:55 AM : Outperform Start Price: $145.37 NASDAQ:STAA Score: -13.33

Big chance to grow

Recs

0
Member Avatar pymwymi (55.14) Submitted: 5/25/2021 5:06:40 PM : Outperform Start Price: $131.45 NASDAQ:STAA Score: -4.75

My most favourite stock for the next 20 years!

Staar Surgical sells the only foldable, minimally invasive implant lenses for people with myopia, who do not prefer glasses or contact lenses.
Adoptation is of Staar's lenses by surgeons and the public, has been steady but slow. This is partly due to regulatory processes and partly due to alternatives which have been around for much longer. Obviously glasses and contact lenses, but also the alternative of laser surgical procedures. In fact, Staar is not really competing with glasses and contact lenses, but is increasingly succesful as an alternative to lasering. Medical research shows favorable results for Staars implants when compared to laser procedures and Staar's market share has been increasing for some time. Outside the US that is. Sales in the US are still relatively small, since regulatory approvals in the US are still pending for an important line of its products. In other major markets, such as Japan, China and Europe, Staar's products are well received and revenue is growing fast there. This alone makes Staar a good company to invest in, but it appears to be just a matter of time before the US market will fully open up, providing even more opportunity for growth.

Estimate for the number of people with mypia globally is 2.6 billion in 2020. This is expected to rise to 3.5 billion people in 2030. Knowing that Staar possesses patents on its implant lenses, the company is optimally positioned to take full benefit of this enormous and still growing markter. Revnue growth rates of between 20 to 30% have been normal for this company for some years, with the exception of the (Covid) year 2020. It wouldn't surprise me if they could sustain such growth rates for the next 10, 20 or even 30 years. 30 years of such growth sounds ridiculous. It would imply that they need to sell about 3 to 4 million of implant lenses per year by 2050. This would equate to 0,1% of all people with myopia at that time globally. Not at all impossible, knowing that its proposition is medically superior to its competitors with Laser technology and knowing that a new, innovative technology, will take a tremendously long time to displace a settled leader.

All of the above makes Staar a stock to buy and never sell. Or at least not in the coming 20 years.

Leaderboard

Find the members with the highest scoring picks in STAA.

Score Leader

stockcaps360

stockcaps360 (62.11) Score: +4,038.31

The Score Leader is the player with the highest score across all their picks in STAA.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
stockcaps360 62.11 9/1/2009 Outperform 5Y $2.95 +4,370.51% +332.20% +4,038.31 0 Comment
frankruediger < 20 8/17/2009 Outperform 1Y $3.03 +4,252.48% +347.20% +3,905.28 0 Comment
bklynmp3j 98.23 8/17/2009 Outperform 5Y $3.03 +4,252.48% +349.06% +3,903.42 2 Comments
Pi4Trepa4 80.60 12/1/2009 Outperform 5Y $3.07 +4,191.29% +295.25% +3,896.05 0 Comment
bullrisk < 20 9/8/2009 Outperform 1Y $3.37 +3,813.35% +329.13% +3,484.23 0 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. keidoandkevin 22.97 7/18/2008 Outperform NS $3.50 +3,668.00% +259.80% +3,408.20 0 Comment
GreatStocks3728 26.56 1/22/2010 Outperform 5Y $3.60 +3,563.44% +295.67% +3,267.77 1 Comment
riddlinroy < 20 6/20/2008 Outperform 3M $3.67 +3,493.46% +244.97% +3,248.49 0 Comment
fireboy23 < 20 6/23/2008 Outperform NS $3.70 +3,464.32% +243.68% +3,220.65 0 Comment
ckaminsky1971 72.81 7/28/2008 Outperform 5Y $3.71 +3,454.72% +261.70% +3,193.02 1 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for STAA.